Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.669 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - oral liquid, solution - excipient ingredients: acesulfame potassium; propyl hydroxybenzoate; purified water; maltitol solution; glycerol; sodium citrate dihydrate; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; flavour - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - azithromycin dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - furosemide, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; sodium chloride - oedema: furosemide ? aft is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. it is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.,furosemide ? aft injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide ? aft is indicated by the intravenous route. parenteral use should be replaced with oral furosemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; cysteine hydrochloride monohydrate; dibasic sodium phosphate dihydrate; mannitol; nitrogen; water for injections; sodium hydroxide - paracetamol-aft 10mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.16 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime-aft is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: ? severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns. ? respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. ? severe ear, nose and throat infections: for example, otitis media, mastoiditis. ? urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. ? skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. ? gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. ? bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.